New Issue: Orbital Catastrophe Ahead? Read Now

Playing Defense against Lou Gehrig's Disease

Researchers have proposed potential therapies for a paralyzing disorder once thought to be untreatable

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


The official name of the illness is amyotrophic lateral sclerosis (ALS), but in the U.S. it is better known as Lou Gehrig’s disease. The great New York Yankees first baseman was diagnosed with ALS in 1939 and died two years later from the progressive neuromuscular disorder, which attacks nerve cells that lead from the brain and the spinal cord to muscles throughout the body. When these motor neurons die, the brain can no longer control muscle movements; in the later stages of the disease, patients become totally paralyzed.

First described in 1869 by French clinician Jean-Martin Charcot, ALS is a misunderstood illness. Doctors once thought it was rare but now consider it fairly common: about 5,000 people in the U.S. are diagnosed with ALS every year. In total there are about 30,000 ALS patients in the U.S. and approximately 5,000 in the U.K. ALS typically develops between the ages of 40 and 70, but the disease strikes younger and older patients as well. Other well-known people who suffered from ALS include British actor David Niven, Russian composer Dmitri Shostakovich and Chinese leader Mao Tse-tung. Researchers have found unusual clusters of patients with the disorder among Italian soccer players, veterans of the Persian Gulf War and residents of the island of Guam, although no one knows why.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe